Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Floris T. M. Bosch"'
Autor:
Tom Arfman, Valentina Zollet, Nick vanEs, Floris T. M. Bosch, Gerry A. F. Nicolaes, Nicoletta Sorvillo, Jan Voorberg
Publikováno v:
eJHaem, Vol 5, Iss 1, Pp 136-140 (2024)
Abstract Neutrophil released peptidyl arginine deiminase 4 (PAD4) converts arginine residues on plasma proteins into citrulline. Here, we developed an assay to quantify citrullinated fibrinogen. We employed a biotin‐conjugated phenylglyoxal (biotin
Externí odkaz:
https://doaj.org/article/81af964bf12e4c81afc00468102d5cf6
Autor:
Nick van Es, Saskia Middeldorp, Floris T. M. Bosch, Pieter Willem Kamphuisen, Patrick M.M. Bossuyt, Frits I. Mulder, Harry R. Büller
Publikováno v:
Blood Adv
Guidelines suggest thromboprophylaxis for ambulatory cancer patients starting chemotherapy with an intermediate to high risk of venous thromboembolism (VTE) according to Khorana score. Data on thromboprophylaxis efficacy in different Khorana score ri
Autor:
Marc Carrier, Floris T. M. Bosch, Annie M. Young, Tyler Zemla, Harry R. Büller, Robert D. McBane, Patrick M.M. Bossuyt, Nick van Es, Frits I. Mulder, Andrea Marshall, Jeffrey I. Weitz, Pieter Willem Kamphuisen, Saskia Middeldorp
Publikováno v:
Blood. 136:1433-1441
Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent results. This systematic review and meta-analysis compared the efficacy and sa
Autor:
Pieter Willem Kamphuisen, Ranjeeta Mallick, Marc Carrier, Phill S Wells, Nick van Es, Frits I. Mulder, Saskia Middeldorp, Floris T. M. Bosch
Publikováno v:
Journal of Thrombosis and Haemostasis, 20, 138-144
Journal of Thrombosis and Haemostasis, 20, 1, pp. 138-144
Journal of thrombosis and haemostasis, 20(1), 138-144. Wiley-Blackwell
Journal of Thrombosis and Haemostasis, 20, 1, pp. 138-144
Journal of thrombosis and haemostasis, 20(1), 138-144. Wiley-Blackwell
Contains fulltext : 248717.pdf (Publisher’s version ) (Open Access) BACKGROUND: Growth differentiation factor-15 (GDF-15) is a strong predictor for bleeding in patients with atrial fibrillation, but there are no data on cardiovascular outcomes for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a08108025e4b86ac55dd05fd07d1a1
http://hdl.handle.net/2066/248717
http://hdl.handle.net/2066/248717
Autor:
Gary E. Raskob, Annelise Segers, Menno V. Huisman, Peter Verhamme, Saskia Middeldorp, Tzu-Fei Wang, Pieter Willem Kamphuisen, Floris T. M. Bosch, Jeffrey I. Zwicker, Nick van Es, David A. Garcia, Anil Duggal, Jeffrey I. Weitz, Harry R. Büller, Michael A. Grosso, Frits I. Mulder, Marc Carrier, Marcello Di Nisio
Publikováno v:
Journal of thrombosis and haemostasis, 19(12), 3008-3017. Wiley-Blackwell
Journal of Thrombosis and Haemostasis, 19, 12, pp. 3008-3017
Journal of Thrombosis and Haemostasis, 19(12), 3008-3017. WILEY
Journal of Thrombosis and Haemostasis, 19, 3008-3017
Journal of Thrombosis and Haemostasis, 19, 12, pp. 3008-3017
Journal of Thrombosis and Haemostasis, 19(12), 3008-3017. WILEY
Journal of Thrombosis and Haemostasis, 19, 3008-3017
BACKGROUND: In the Hokusai VTE Cancer study, the risk of major bleeding was 2.9% higher in the edoxaban group compared with the dalteparin group, mainly due to more gastrointestinal bleedings in patients with gastrointestinal cancer. The identificati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ffadf52633ecf6ab6a8890f22669072
https://pure.amc.nl/en/publications/risk-factors-for-gastrointestinal-bleeding-in-patients-with-gastrointestinal-cancer-using-edoxaban(a4d44fb1-a407-4335-8fd8-c7529fc98867).html
https://pure.amc.nl/en/publications/risk-factors-for-gastrointestinal-bleeding-in-patients-with-gastrointestinal-cancer-using-edoxaban(a4d44fb1-a407-4335-8fd8-c7529fc98867).html
Autor:
Marcello Di Nisio, Ettore Porreca, Pieter Willem Kamphuisen, Nicola Potere, Floris T. M. Bosch, Matteo Candeloro
Publikováno v:
Thrombosis research, 205, 106-109. Elsevier Limited
Thrombosis Research
Thrombosis Research
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9d8d0ae627d573e07feee31f9def7bf
https://pure.amc.nl/en/publications/effect-of-dexamethasone-on-direct-xainhibitor-oral-anticoagulant-plasma-levels-in-patients-with-covid19(a66a2ec3-8625-42e8-9e53-57b9f1c06b82).html
https://pure.amc.nl/en/publications/effect-of-dexamethasone-on-direct-xainhibitor-oral-anticoagulant-plasma-levels-in-patients-with-covid19(a66a2ec3-8625-42e8-9e53-57b9f1c06b82).html
Autor:
Harry R. Büller, Noori A.M. Guman, Floris T. M. Bosch, Pieter Willem Kamphuisen, Saskia Middeldorp, Inge A. Gimbel, Nick van Es, Jan Erik Freund, Frits I. Mulder
Publikováno v:
Journal of Thrombosis and Haemostasis, 19, 1228-1235
Journal of Thrombosis and Haemostasis, 19, 5, pp. 1228-1235
Journal of thrombosis and haemostasis, 19(5), 1228-1235. Wiley-Blackwell
Journal of Thrombosis and Haemostasis, 19, 5, pp. 1228-1235
Journal of thrombosis and haemostasis, 19(5), 1228-1235. Wiley-Blackwell
Contains fulltext : 245712.pdf (Publisher’s version ) (Open Access) BACKGROUND: Pulmonary embolism (PE) is a potentially fatal disease, but data on the incidence of fatal PE in cancer patients are scant. OBJECTIVE: We sought to estimate the proport
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ec9235c2b6feeb8161154bc663851e9
http://hdl.handle.net/2066/245712
http://hdl.handle.net/2066/245712
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 9, Iss 2069, p 2069 (2020)
Journal of Clinical Medicine, Vol 9, Iss 2069, p 2069 (2020)
Upper extremity deep vein thrombosis (UEDVT) accounts for 5% of all deep vein thromboses (DVTs). UEDVT may be complicated by post thrombotic syndrome and pulmonary embolism, and early recognition and prompt start of anticoagulant treatment are key. P
Publikováno v:
Cancers, Vol 12, Iss 2, p 367 (2020)
Cancers
Cancers
Venous thromboembolism (VTE), comprising deep-vein thrombosis and pulmonary embolism, is a frequent complication in ambulatory cancer patients. Despite the high risk, routine thromboprophylaxis is not recommended because of the high number needed to
Autor:
Marc Carrier, H. R. Büller, Floris T. M. Bosch, Frits I. Mulder, Michael A. Grosso, M. Di Nisio, David A. Garcia, Peter Verhamme, Jeffrey I. Weitz, Tzu-Fei Wang, Jean M. Connors, Annelise Segers, N. van Es, Gary E. Raskob
Publikováno v:
Thrombosis Research. 200:S14-S15